



## PD Dr med Arnoud Templeton

### Contact

PD Dr med Arnoud Templeton  
Switzerland

### Units

Medizinische Onkologie und Hämatologie

## Publications (62)

Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. Behandlung des fortgeschrittenen Prostatakarzinoms - eine interdisziplinäre Empfehlung. Schweiz Rundschau Med (PRAXIS) 2018; 107:1043-51.

Ocana A, Pandiella A, Andrés-Pretel F, Seruga B, Corrales-Sanchez V, Serrano-Heras G, Gascon-Escribano M, Vera-Badillo F, Templeton A, Garcia-Olmo D, Diez-Gonzalez L, Amir E. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev 2015

AlHashem H, Al-Mubarak M, Vera-Badillo F, Templeton A, Ocana A, Šeruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol) 2015

Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. Eur Urol 2015

Ocana A, Pandiella A, Niraula S, Seruga B, Vera-Badillo F, Templeton A, Gascón-Escribano M, Srikanthan A, Corrales-Sanchez V, Diez-Gonzalez L, Ethier J, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015

Templeton A, Šeruga B. Primum non nocere. Ann Oncol 2015; 26:2197-8.

Vera-Badillo F, Tannock I, Bedard P, Goldstein R, Seruga B, Templeton A, Ocana A, Kuruzar G, Chang M, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol 2015

Templeton A, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond G, Tannock I. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer 2015

Schlaeppli M, Templeton A. Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie. Onkologische Pharmazie 2015; 1:46-50.

Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014

van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 2014

Kroeger N, Smoragiewicz M, Lee J, Rini B, Vaishampayan U, Wood L, Beuselinck B, Donskov F, Choueiri T, Bernstein E, Knox J, Templeton A, Pantuck A, Wells J, Lawrence N, Broom R, Kim J, Srinivas S, Yim J, Bjarnason G, Heng D. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol 2014

<p>Rocha P, Morgan C, Templeton A, Pond G, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. <i>Oncol Res Treat</i> 2014; 37:772-6.</p>
<p>Tibau A, Barnadas A, Seruga B, Ocana A, Templeton A, Vera-Badillo F, Ethier J, Srikanthan A, Bedard P, Amir E. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. <i>J Clin Oncol</i> 2014; 33:100-6.</p>
<p>Shao T, Shoushtari H, Sinaei M, Kim T, Margolis M, McNamara M, Vera-Badillo F, Jang R, Templeton A, Wang L, Tannock I. Use and misuse of waterfall plots. <i>J Natl Cancer Inst</i> 2014; 106</p>
<p>Leibowitz-Amit R, Templeton A, Alibhai S, Knox J, Sridhar S, Tannock I, Joshua A. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>J Geriatr Oncol</i> 2014; 6:23-8.</p>
<p>Schlaeppli M, Templeton A. Komplementärmedizin in der Onkologie - Was der Grundversorger wissen sollte. <i>Swiss Medical Forum</i> 2014; 14:689-693.</p>
<p>Templeton A, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocana A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. <i>Cancer Treat Rev</i> 2014; 40:1048-55.</p>
<p>Leibowitz-Amit R, Alimohamed N, Vera-Badillo F, Seah J, Templeton A, Knox J, Tannock I, Sridhar S, Joshua A. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. <i>Prostate</i> 2014; 74:1462-4.</p>
<p>Vera-Badillo F, Ocana A, Templeton A, Tibau A, Amir E, Tannock I. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. <i>J Clin Oncol</i> 2014; 32:3197.</p>
<p>Leibowitz-Amit R, Sridhar S, Tannock I, Knox J, Alimohamed N, Vera-Badillo F, Templeton A, Atenafu E, Seah J, Joshua A. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. <i>Eur J Cancer</i> 2014; 50:2399-407.</p>
<p>Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> 2014; 120:3346-52.</p>
<p>Vera-Badillo F, Napoleone M, Ocana A, Templeton A, Seruga B, Al-Mubarak M, AlHashem H, Tannock I, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Res Treat</i> 2014; 146:235-44.</p>
<p>Hermanns T, Templeton A, Zlotta A, Fleshner N, Jewett M, Almatar A, Bhatt J, Richard P, Noon A, Yu J, Wei Y, Bhindi B, Kulkarni G. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Br J Cancer</i> 2014; 111:444-51.</p>
<p>Vera-Badillo F, Escudier B, Tannock I, Knox J, Aneja P, de Gouveia P, Ocana A, Duran I, Templeton A, Amir E. Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2014</p>
<p>Templeton A, Tannock I, Tran B, Knox J, Sonpavde G, Leibowitz-Amit R, Ocana A, Aneja P, Vera-Badillo F, Seruga B, McNamara M, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>J Natl Cancer Inst</i> 2014; 106:dju124.</p>

Templeton A, Tannock I, Ocana A, Seruga B, Hermanns T, Vera-Badillo F, Al-Mubarak M, McNamara M, Ace O, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2014; 23:1204-12.

Ocana A, Pandiella A, Seruga B, Cuenca-Lopez M, Diez-Gonzalez L, Corrales-Sanchez V, Templeton A, Al-Mubarak M, Vera-Badillo F, Amir E. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. *PLoS one* 2014; 9:e95219.

Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). *Breast* 2014; 23:244-9.

Sonpavde G, Smith M, Lechuga M, Chow-Maneval E, Chen I, Paolini J, Wang S, Templeton A, Vardy J, Clarke S, Armstrong A, Pond G, Michaelson M. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer* 2014; 12:317-24.

McNamara M, Templeton A, Maganti M, Walter T, Horgan A, McKeever L, Min T, Amir E, Knox J. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. *Eur J Cancer* 2014; 50:1581-9.

Al-Mubarak M, Tibau A, Templeton A, Cescon D, Ocana A, Seruga B, Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. *PLoS one* 2014; 9:e88238.

McNamara M, Laperriere N, Millar B, Chung C, Bernstein M, Zadeh G, Templeton A, Jiang H, Lwin Z, Mason W. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. *J Neurooncol* 2014; 117:147-52.

Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. *Ann Oncol* 2014; 25:657-62.

Rothermundt C, Cathomas R, Rüschoff J, Schiess R, Endt K, Lui L, Pollak M, Bärtschi D, Strebel R, Winterhalder R, Templeton A, Hayoz S, Gillessen Sommer S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). *Eur Urol* 2014; 66:468-74.

Vera-Badillo F, Ocana A, Tannock I, Seruga B, Al-Mubarak M, Bedard P, Diaz-Padilla I, de Gouveia P, Templeton A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* 2013; 106:djt319.

Templeton A, Amir E, Pond G, Joshua A, Sridhar S, Moore M, Knox J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F, Tannock I. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. *Ann Oncol* 2013; 24:2972-7.

Vera-Badillo F, Al-Mubarak M, Templeton A, Amir E. Benefit and harms of new anti-cancer drugs. *Curr Oncol Rep* 2013; 15:270-5.

Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebbersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). *Eur Urol* 2013; 64:150-8.

Hochstrasser A, Benz G, Jörger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. *Chemotherapy* 2012; 58:84-88.

Templeton A, Schlaeppi M. Anthroposophische Konzepte naturwissenschaftlich beleuchtet. *Schweizerische Ärztezeitung* 2011; 92:1558-1559.

Kaelin M, Krek W, Aebersold R, Cerny T, Templeton A, Wild P, Powles T, Fankhauser N, Schiess R, Cima I, Gillessen Sommer S. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. *Eur Urol* 2011; 60:1235-43.

Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schöffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. *Proc Natl Acad Sci USA* 2011; 108:3342-7.

Gillessen Sommer S, Templeton A, Marra G, Kuo Y, Valtorta E, Shahinian V. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. *J Natl Cancer Inst* 2010; 102:1760-70.

Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. *Cancer Chemother Pharmacol* 2010

Templeton A, Rothermundt C. Metastasiertes Nierenzellkarzinom – Moderne Behandlung bei fortgeschrittenem Stadium. *Ars Medici* 2010; 15:598-602.

Omlin A, Kaelin M, Templeton A, Jungi M, Gillessen Sommer S, Graf H, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie. *Swiss Medical Forum* 2010; 10:483-485.

Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. *Chemotherapy* 2010; 56:69-70.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribl K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). *Onkologie* 2010; 33:222-8.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribl K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. *Onkologie* 2010; 33:222-228.

Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen Sommer S, Cathomas R. Primary manifestation of small lymphocytic lymphoma in the prostate. *Onkologie* 2009; 32:586-8.

Fokt R, Templeton A, Gillessen Sommer S, Öhlschlegel C, Schmid H. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. *Urol Int* 2009; 83:122-4.

Templeton A, Thürlimann B, Jörger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. *Schweizer Krebsbulletin* 2009:114-117.

Templeton A, Marra G, Valtorta E, Heinemann K, Müller H, Köberle D, Gillessen Sommer S. Concordant colon tumors in monozygotic twins previously treated for prostate cancer. *Familial cancer* 2009; 8:167-71.

Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S, Eich G. Multilumen central venous catheters increase risk for catheter-related bloodstream infection: prospective surveillance study. *Infection* 2008; 36:322-7.

Templeton A, Hofer S, Toepfer M, Sommacal A, Fretz C, Cerny T, Gillessen Sommer S. Extraneural spread of glioblastoma--report of two cases. *Onkologie* 2008; 31:192-4.

Templeton A, Brändle M, Cerny T, Gillessen Sommer S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2008; 19:824-5.

Templeton A, Omlin A, Strasser F. An update on the pharmacological management of the cancer anorexia-cachexia-syndrome. *European Journal of Palliative Care* 2007; 14:186-190.

Templeton A, Gillessen Sommer S. Sinnvoll?. *Schweiz Med Forum* 2007; 7:469.

Templeton A, Engeler S, Boggian K. Varizellenpneumonie. *Schweiz Med Forum* 2006; 6

Rafeiner P, Templeton A, Vonesch H. Swollen leg with blisters. *Praxis* 2005; 94:1569-74.

Templeton A, Vonesch H. Intoxikation mit GBL ("liquid ecstasy"). *Schweiz Med Forum* 2005; 5:115-116.

## Projects (10)

### **Characterization of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland**

*Clinical Studies - Jul 7, 2020 - Jul 7, 2021*

*Completed*

### **An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors**

*Clinical Studies - Jul 8, 2015 - Jul 31, 2019*

*Automatically Closed*

### **A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (ANTI-PD-L1 ANTIBODY) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy. GO29294**

*Clinical Studies - Apr 2, 2015 - Dec 1, 2016*

*Automatically Closed*

### **SAKK 63/12 Prospective cohort study with collection of clinical data and serum of patients with prostate disease**

*Clinical Studies - Oct 15, 2014 - Oct 15, 2024*

*Ongoing*

### **Retrospective Analysis of mistletoe-induced fever in cancer patients**

*Clinical Studies - Mar 1, 2012 - Dec 31, 2014*

*Completed*

### **Metformin in castration resistant prostate cancer. A multicenter phase II trial**

*Clinical Studies - Nov 16, 2010 - Sep 30, 2012*

*Completed*

### **Local antiperspirant for prevention of palmar-plantar erythrodysesthesia (PPE) in patients treated with pegylated liposomal doxorubin: A randomized, multicenter, double blinded, phase III trial**

*Clinical Studies - Sep 23, 2009 - Jun 30, 2011*

*Completed*

### **SAKK 08/08: Everolimus als Erstlinienbehandlung des Kastrationsrefraktären Prostatakarzinoms – Eine multizentrische Phase II Studie**

*Clinical Studies - Sep 3, 2009 - Jul 31, 2013*

*Completed*

### **What "extras" do breast cancer patients receiving adjuvant therapy ask for?**

*Clinical Studies - Dec 1, 2008 - Jun 30, 2013*

*Completed*

**Multiepitop Impfung von Grad III/IV Melanopatienten mit dendritischen Zellen: Bedeutung von Peptidaffinität und -dichte für die optimale Generierung von tumorspezifischen zytotoxischen T-Lymphozyten**

*Clinical Studies - Jan 1, 2007 - Dec 31, 2009*

*Completed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch